Novo and Lilly Pills Draw Patients From Compounded Drugs
Lower costs for oral versions of Wegovy and Foundayo are prompting U.S. patients to switch from compounded medications to branded treatments. Doctors report that while insurance hurdles remain, the competitive pricing and established brand recognition are expanding the market for GLP-1 therapies.
Xurve View
洞察:
Xurve View
NOVO-NORDISK A/S-SPONS ADR and ELI LILLY & CO are capturing market share from compounded drug pharmacies with oral weight-loss treatments priced at $149 per month. These pill versions cost around $149 compared to $199–$299 for their respective injectable counterparts in the United States. The pricing shift targets self-pay patients and addresses regulatory limits on personalized formulations after years of branded drug shortages.
